TTOO Capex To Revenue vs Ev To Sales Analysis
TTOO Stock | USD 0.39 0.06 14.33% |
T2 Biosystms financial indicator trend analysis is much more than just breaking down T2 Biosystms prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether T2 Biosystms is a good investment. Please check the relationship between T2 Biosystms Capex To Revenue and its Ev To Sales accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
Capex To Revenue vs Ev To Sales
Capex To Revenue vs Ev To Sales Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of T2 Biosystms Capex To Revenue account and Ev To Sales. At this time, the significance of the direction appears to have very strong relationship.
The correlation between T2 Biosystms' Capex To Revenue and Ev To Sales is 0.82. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of T2 Biosystms, assuming nothing else is changed. The correlation between historical values of T2 Biosystms' Capex To Revenue and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of T2 Biosystms are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Capex To Revenue i.e., T2 Biosystms' Capex To Revenue and Ev To Sales go up and down completely randomly.
Correlation Coefficient | 0.82 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most indicators from T2 Biosystms' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into T2 Biosystms current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.As of the 13th of December 2024, Enterprise Value is likely to grow to about 75.5 M, while Selling General Administrative is likely to drop about 26 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 6.6M | 6.1M | 5.3M | 4.9M | Depreciation And Amortization | 2.5M | 2.3M | 859K | 1.1M |
T2 Biosystms fundamental ratios Correlations
Click cells to compare fundamentals
T2 Biosystms Account Relationship Matchups
High Positive Relationship
High Negative Relationship
T2 Biosystms fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 28.5M | 79.1M | 60.5M | 34.4M | 34.8M | 43.7M | |
Short Long Term Debt Total | 44.8M | 55.8M | 57.1M | 59.2M | 49.5M | 42.0M | |
Other Current Liab | 13.6M | 6.4M | 7.2M | 6.0M | 9.9M | 6.8M | |
Total Current Liabilities | 60.6M | 9.8M | 11.7M | 10.5M | 56.2M | 59.0M | |
Total Stockholder Equity | (34.0M) | 8.7M | (12.9M) | (40.0M) | (28.0M) | (26.6M) | |
Other Liab | 46K | 4.8M | 4.6M | 4.9M | 5.6M | 5.9M | |
Property Plant And Equipment Net | 9.2M | 14.8M | 14.4M | 13.3M | 9.1M | 9.8M | |
Net Debt | 33.7M | 39.0M | 34.9M | 48.9M | 33.8M | 35.5M | |
Retained Earnings | (376.2M) | (423.0M) | (472.2M) | (534.5M) | (584.3M) | (555.1M) | |
Accounts Payable | 3.8M | 2.1M | 2.8M | 1.3M | 1.5M | 1.6M | |
Cash | 11.0M | 16.8M | 22.2M | 10.3M | 15.7M | 28.6M | |
Non Current Assets Total | 9.6M | 25.5M | 16.1M | 15.0M | 9.6M | 11.6M | |
Cash And Short Term Investments | 11.0M | 42.2M | 32.2M | 10.3M | 15.7M | 31.0M | |
Common Stock Total Equity | 36K | 44K | 51K | 147K | 169.1K | 177.5K | |
Common Stock Shares Outstanding | 9.1K | 24.3K | 31.8K | 51.0K | 2.6M | 2.7M | |
Liabilities And Stockholders Equity | 28.5M | 79.1M | 60.5M | 34.4M | 34.8M | 43.7M | |
Non Current Liabilities Total | 1.9M | 60.6M | 61.8M | 63.9M | 6.7M | 6.3M | |
Other Current Assets | 1.4M | 2.7M | 3.1M | 2.6M | 3.3M | 1.7M | |
Other Stockholder Equity | 342.1M | 431.5M | 459.2M | 494.6M | 556.3M | 315.0M | |
Total Liab | 62.5M | 70.4M | 73.4M | 74.4M | 62.8M | 50.8M | |
Property Plant And Equipment Gross | 9.2M | 14.8M | 14.4M | 13.3M | 23.9M | 25.1M | |
Total Current Assets | 18.9M | 53.6M | 44.4M | 19.4M | 25.2M | 35.3M | |
Short Term Debt | 42.9M | 1.2M | 1.2M | 2.7M | 44.5M | 46.7M | |
Common Stock | 49K | 147K | 166K | 8K | 4K | 3.8K | |
Property Plant Equipment | 5.8M | 14.8M | 14.4M | 13.3M | 15.3M | 9.5M | |
Net Tangible Assets | (32.1M) | 8.7M | (12.9M) | (40.0M) | (36.0M) | (34.2M) | |
Current Deferred Revenue | 285K | 230K | 518K | 172K | 224K | 212.8K | |
Net Receivables | 2.8M | 5.1M | 5.1M | 2.2M | 1.4M | 2.2M | |
Retained Earnings Total Equity | (266.1M) | (317.2M) | (376.2M) | (423.0M) | (380.7M) | (399.7M) | |
Capital Surpluse | 267.4M | 328.5M | 342.1M | 431.5M | 496.3M | 308.8M | |
Inventory | 3.6M | 3.6M | 3.9M | 4.3M | 4.8M | 2.9M | |
Short Long Term Debt | 40.7M | 42.4M | 42.9M | 41.3M | 47.5M | 27.2M | |
Capital Lease Obligations | 3.9M | 10.5M | 9.4M | 9.6M | 8.2M | 6.1M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.999 | Quarterly Revenue Growth (0.01) | Return On Assets (0.90) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.